Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

532
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
532
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

591
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
591
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

598
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
598
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

478
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
478
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

621
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
621
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

367
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrophysiological characterization of the Bachmann bundle region using 3D electroanatomical mapping and peak frequency analysis during pacemaker lead implantation.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Repolarization and Activation Mapping in Ventricular Tachycardia Ablation: The REDEEM Study.

JACC. Clinical electrophysiology·2026
Same author

Incidence, Mechanistic Insights, and Ablation of Atrial Tachycardia Occurring After Pulsed Field Ablation for Atrial Fibrillation: Results From a Large International Registry.

JACC. Clinical electrophysiology·2026
Same author

Resetting the clock: Short-term narratives and long-term realities in transcatheter valve trials.

JTCVS structural and endovascular·2026
Same author

Tricuspid valve repair in infective endocarditis.

Annals of cardiothoracic surgery·2026
Same author

Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation Patients at Very High Risk of Stroke: A Budget Impact Analysis in Italy.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Feb 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Hypertrophic obstructive cardiomyopathy: what, when, why, for whom?

Carlos A Mestres1,2, Thomas Bartel3, Antonio Sorgente3

  • 1Department of Cardiovascular Surgery, Herzzentrum University Hospital Zürich, Zürich, Switzerland.

European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|February 14, 2018
PubMed
Summary

Surgical septal myectomy is a highly effective treatment for obstructive hypertrophic cardiomyopathy, offering immediate relief and long-term survival benefits compared to alcohol septal ablation.

More Related Videos

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

7.2K

Related Experiment Videos

Last Updated: Feb 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

7.2K

Area of Science:

  • Cardiology
  • Genetics
  • Cardiac Surgery

Background:

  • Hypertrophic cardiomyopathy (HCM) is a primary genetic heart disease.
  • HCM often leads to left ventricular outflow tract obstruction (LVOTO), heart failure, and sudden cardiac death.
  • Septal reduction therapy is indicated for symptomatic severe LVOTO (gradient ≥50 mmHg).

Purpose of the Study:

  • To compare the efficacy and outcomes of surgical septal myectomy and alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
  • To evaluate the long-term benefits and risks associated with each septal reduction therapy.

Main Methods:

  • Review of existing literature and clinical data comparing surgical septal myectomy and alcohol septal ablation.
  • Analysis of patient outcomes including mortality, obstruction resolution, functional improvement, and need for further interventions.

Main Results:

  • Alcohol septal ablation offers a less invasive approach with functional improvement but carries risks of intracardiac device implantation and residual obstruction.
  • Surgical septal myectomy demonstrates very low mortality, immediate and complete LVOTO resolution, and survival comparable to the general population with minimal residual obstruction.
  • Septal myectomy provides superior long-term outcomes regarding obstruction resolution.

Conclusions:

  • Surgical septal myectomy is recommended for its superior efficacy in resolving LVOTO and long-term survival benefits in obstructive hypertrophic cardiomyopathy.
  • Patients with obstructive hypertrophic cardiomyopathy should seek treatment at specialized centers with expertise in these procedures.